Bavarian Nordic intends to boost its output of the Mpox vaccine.
Danish pharmaceutical firm Bavarian Nordic plans to ramp up its production of the Monkeypox vaccine. By 2025's end, they intend to churn out a whopping ten million doses, as per their recent announcement. As early as this year, they've predicted delivering two million doses. The African CDC has been notified about this development. Bavarian Nordic is aiming to join forces with the CDC and the World Health Organization (WHO), working tirelessly to assure equitable distribution worldwide. The WHO has officially categorized the Monkeypox virus-related illness as a global health crisis.
The Monkeypox virus-induced outbreak that began in the Democratic Republic of Congo in January 2023 has resulted in approximately 27,000 known cases and over 1,100 fatalities, primarily impacting children. Swedish health authorities confirmed the first instance of a new Monkeypox variant outside of Africa last Thursday.**
Bavarian Nordic's collaboration with the CDC and WHO in Monkeypox vaccine production is aimed at ensuring equitable distribution globally. This cooperation could significantly help in controlling the ongoing Monkeypox virus outbreak, given the high numbers of reported cases and fatalities.
